Medulloepithelioma is a rare primitive neuroectodermal tumor of the central nervous system usually developing in childhood, displaying highly malignant behavior, with early progression or recurrence. Once a recurrence develops, death reportedly follows with invariable rapidity. The purpose of this study was to evaluate the efficacy of high-dose, marrow-ablative chemotherapy with autologous hemopoietic stem cell rescue in the treatment of recurrent central nervous system medulloepithelioma. Three young children with recurrent central nervous system medulloepithelioma received high-dose marrow-ablative chemotherapy with thiotepa and etoposide either alone (one patient) or with the addition of carboplatin (two patients). This was followed by irradiation only in one patient. One child with residual radiographic tumor at the time of treatment could be evaluated for response and showed complete resolution of leptomeningeal disease after receiving marrow-ablative chemotherapy. Two children developed tumor recurrence at 2.0 and 5.5 months after receiving marrow-ablative chemotherapy. The third child continues free of tumor beyond 12 years from treatment. The authors' experience with marrow-ablative chemotherapy and autologous hemopoietic stem cell rescue suggests that this treatment strategy might be beneficially incorporated into the initial treatment approach for young children with medulloepithelioma.
From the *Department of Pediatrics, New York University School of Medicine, New York, NY; †Department of Neurosurgery, New York University School of Medicine, New York, NY; ‡Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY; §Department of Pathology, New York University School of Medicine, New York, NY; ∥Division of Pediatric Oncology, Columbia Children's Hospital, New York, NY; ¶Department of Neuropathology, Children's Hospital of Philadelphia, Philadelphia, PA; and **Neural Tumors Program, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA.
Received for publication November 23, 2004; accepted March 30, 2005.
Reprints: Jonathan L. Finlay, Children's Center for Cancer & Blood Diseases, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Mail Stop #54, Los Angeles, CA 90027 (e-mail: email@example.com).